Approximately one-third of human breast cancer patients derive a significant clinical benefit from some type of endocrine therapy. These therapeutic procedures are generally designed to either decrease estrogen production in the patient or interfere with its action. A large body of experimental evidence supports the hypothesis that the growth of breast tumors is directly dependent upon estrogen. Identification of the subset of human breast cancer patients that are likely to respond to endocrine therapy is a prime clinical priority. Basic research on the mechanism of estrogen action has led to the identification and characterization of the estrogen receptor protein. Large-scale screenings of breast tumors for the presence of the estrogen receptor have demonstrated a positive correlation between the presence of the protein and the probability of responding to therapy. Current studies are directed at understanding the mechanism of receptor-mediated tumor growth and the progression of breast cancer tumors to a hormone-independent state.
|Original language||English (US)|
|Number of pages||9|
|Journal||ISI Atlas of Science: Pharmacology|
|State||Published - Jan 1 1988|
ASJC Scopus subject areas
- Pharmacology, Toxicology and Pharmaceutics(all)